Drugs / Emactuzumab
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03369964 | Mar → Dec 2018 | non-Hodgkin lymphoma | Hoffmann-La Roche | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02760797 | May 2016 → Apr 2018 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02323191 | Jan 2015 → Aug 2020 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01494688 | Dec 2011 → Feb 2018 | cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02923739 | May 2017 → Sep 2022 | fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma +10 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05417789 | Oct 2024 → Dec 2025 overdue | giant cell tumor of soft tissue | SynOx Therapeutics Limited | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03768063 | Feb 2019 → Jul 2028 expected | cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-13 | SynOx Therapeutics Limited | Results SynOx Therapeutics announces positive topline results from the Phase 3 TANGENT study synoxtherapeutics.com ↗
SynOx Therapeutics Limited (“SynOx”) today announced positive topline results from the pivotal Phase 3 TANGENT study of emactuzumab in adult patients with TGCT. |
| 2025-04-14 | SynOx Therapeutics Limited | Regulatory SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) synoxtherapeutics.com ↗
today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to emactuzumab for the treatment of TGCT patients that are not amenable to or who would not benefit from surgery. |
| 2022-08-31 | SynOx Therapeutics Limited | Regulatory Emactuzumab designated as an Orphan Medicinal Product in Europe synoxtherapeutics.com ↗
The European Medicines Agency (EMA) has designated emactuzumab as an orphan medicinal product in the indication of TGCT for both localized and diffuse types of the disease. |
All press releases naming this drug 6 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emactuzumab | “Emactuzumab (RG7155) is a novel monoclonal antibody that inhibits CSF1R activation.” PMID 26179200 ↗ Jul 2015 |
| Known as | 7i1955n5wx | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545370 ↗ |
| Known as | CXD-301 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545370 ↗ |
| Known as | RG-7155 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545370 ↗ |
| Known as | RO-5509554 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545370 ↗ |
| Known as | RO5509554 (ANTI-CSF-R1) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545370 ↗ |
| Action | Inhibit | “inhibits CSF1R activation” PMID 26179200 ↗ Jul 2015 |
| Modality | Monoclonal antibody | “a humanised anti-colony stimulating factor 1 receptor (CSF1R) monoclonal antibody” PMID 33161240 ↗ Nov 2020 |
| Route | Intravenous | “Patients received intravenous (IV) emactuzumab” PMID 33161240 ↗ Nov 2020 |
| Target | CSF1R | “Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab” PMID 35577503 ↗ May 2022 |